Literature DB >> 1800459

Optimal antibody-radionuclide combinations for clinical radioimmunotherapy: a predictive model based on mouse pharmacokinetics.

E D Yorke1, P L Beaumier, B W Wessels, A R Fritzberg, A C Morgan.   

Abstract

A theoretical comparison was made of radioimmunotherapy (RIT) dosimetry estimates for eight radionuclides (90Y, 105Rh, 131I, 153Sm, 186Re, 188Re, 198Au, 211At) conjugated to IgG, F(ab')2, and Fab antibody forms. Antibody pharmacokinetics, derived from a nude mouse animal model were combined with appropriate physical data and S values to evaluate absorbed dose to a 0.5 kg centrally located tumor, total body and kidney. Radioimmunoconjugates of F(ab')2 with 90Y, 153Sm and 186Re were predicted to be the most promising for RIT.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1800459     DOI: 10.1016/0883-2897(91)90090-8

Source DB:  PubMed          Journal:  Int J Rad Appl Instrum B        ISSN: 0883-2897


  6 in total

1.  Exploring oxorhenium '3+1' mixed-ligand complexes carrying the S-benzyl-3-[(2-hydroxyphenyl)methylene]dithiocarbazate [ONS]/monothiol [S] donor set: synthesis and characterization.

Authors:  Xiaoyuan Chen; Frank J Femia; John W Babich; Jon Zubieta
Journal:  Inorganica Chim Acta       Date:  2000-09-11       Impact factor: 2.545

2.  Uranium-loaded apoferritin with antibodies attached: molecular design for uranium neutron-capture therapy.

Authors:  J F Hainfeld
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-15       Impact factor: 11.205

3.  Radioimmunotherapy of colorectal carcinoma xenografts in nude mice with yttrium-90 A33 IgG and Tri-Fab (TFM).

Authors:  P Antoniw; A P Farnsworth; A Turner; A M Haines; A Mountain; J Mackintosh; D Shochat; J Humm; S Welt; L J Old; G T Yarranton; D J King
Journal:  Br J Cancer       Date:  1996-08       Impact factor: 7.640

4.  Preparation, characterisation and tumour targeting of cross-linked divalent and trivalent anti-tumour Fab' fragments.

Authors:  J L Casey; D J King; L C Chaplin; A M Haines; R B Pedley; A Mountain; G T Yarranton; R H Begent
Journal:  Br J Cancer       Date:  1996-11       Impact factor: 7.640

5.  Prolonged in vivo tumour retention of a human diabody targeting the extracellular domain of human HER2/neu.

Authors:  G P Adams; R Schier; A M McCall; R S Crawford; E J Wolf; L M Weiner; J D Marks
Journal:  Br J Cancer       Date:  1998-05       Impact factor: 7.640

6.  Enhanced tumour specificity of an anti-carcinoembrionic antigen Fab' fragment by poly(ethylene glycol) (PEG) modification.

Authors:  C Delgado; R B Pedley; A Herraez; R Boden; J A Boden; P A Keep; K A Chester; D Fisher; R H Begent; G E Francis
Journal:  Br J Cancer       Date:  1996-01       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.